Differential expression and activation of NF-κB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection

International Journal of Cancer

Volumn 119, Issue 12, 2006, Pages 2840-2850

  Mishra, Alok ^a   Bharti, Alok C ^a   Varghese, Prishla ^a   Saluja, Daman ^b   Das, Bhudev C ^a  

^a Institute of Cytology and Preventive Oncology ICMR   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

Bcl 3; Carcinogenesis; Constitutive activation; High risk HPV; Human papillomavirus; NF B; Oral cancer

Indexed keywords

HOMODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 3; PROTEIN P50; PROTEIN P52; PROTEIN SUBUNIT; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELB;

ADULT; ARTICLE; CANCER RISK; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GEL MOBILITY SHIFT ASSAY; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDIA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; ORAL BIOPSY; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; SOUTHEAST ASIA; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR DIFFERENTIATION; UPREGULATION; VIRUS DIAGNOSIS; VIRUS INFECTION; WART VIRUS; WESTERN BLOTTING;

ADULT; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, VIRAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOUTH NEOPLASMS; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; OLIGONUCLEOTIDES; PAPILLOMAVIRUS INFECTIONS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RISK FACTORS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TRANSCRIPTION FACTORS;

EID: 33751585152     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22262     Document Type: Article

References (81)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000 - cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5. Lyon: IARC, 2001.
3. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernandez L, Idris A, Sanchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJ, Meijer CJ, Viscidi R, Munoz N, Franceschi S. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-83.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
5. Donofrio V, Lo Muzio L, Mignogna MD, Troncone G, Staibano S, Boscaino A, De Rosa G. Prognostic evaluation of HPV-associated precancerous and microinvasive carcinoma of the oral cavity: combined use of nucleolar organiser regions (AgNOR) and proliferating cell nuclear antigen (PCNA). Eur J Cancer B Oral Oncol 1995;31:174-80.
6. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001;125:1-9.
7. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP, Haugen TH. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336-44.
8. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005;32 (Suppl. 1):S59-S66.
9. Pintos J, Franco EL, Black MJ, Bergeron J, Arella M. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 1999;85:1903-9.
10. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-κB transcription factor and cancer: high expression of NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145-9.
11. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr, Sledge GW, Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39.
12. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-60.
13. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
14. Dokter WH, Tuyt L, Sierdsema SJ, Esselink MT, Vellenga E. The spontaneous expression of interleukin-1β and interleukin-6 is associated with spontaneous expression of AP-1 and NF-κB transcription factor in acute myeloblastic leukemia cells. Leukemia 1995;9:425-32.
15. Miyamoto S, Chiao PJ, Verma IM. Enhanced I κB α degradation is responsible for constitutive NF-κB activity in mature murine B-cell lines. Mol Cell Biol 1994;14:3276-82.
16. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-62.
17. Prusty BK, Husain SA, Das BC. Constitutive activation of nuclear factor -κB: preferntial homodimerization of p50 subunits in cervical carcinoma. Front Biosci 2005;10:1510-19.
18. Shishodia S, Aggarwal BB. Nuclear factor-κB: a friend or a foe in cancer? Biochem Pharmacol 2004;68:1071-80.
19. Fontaine V, van der Meijden E, de Graaf J, ter Schegget J, Struyk L. A functional NF-κB binding site in the human papillomavirus type 16 long control region. Virology 2000;272:40-9.
20. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C. Constitutive activation of transcription factors NF-κB, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999;26:119-29.
21. Spitkovsky D, Hehner SP, Hofmann TG, Moller A, Schmitz ML. The human papillomavirus oncoprotein E7 attenuates NF-κB activation by targeting the IκB kinase complex. J Biol Chem 2002;277:25576-82.
22. Havard L, Rahmouni S, Boniver J, Delvenne P. High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins. Virology 2005;331:357-66.
23. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999;18:6853-66.
24. Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-κB/Rel transcription factors defines functional specificities. Embo J 2003;22:5530-9.
25. Lernbecher T, Muller U, Wirth T. Distinct NF-κB/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature 1993;365:767-70.
26. Perkins ND. Achieving transcriptional specificity with NF-κB. Int J Biochem Cell Biol 1997;29:1433-48.
27. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor a transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 1990;10:1498-506.
28. Schouten GJ, van der Eb AJ, Zantema A. Downregulation of MHC class I expression due to interference with p105-NF κB1 processing by Ad12E1A. Embo J 1995;14:1498-507.
29. Das BC, Sharma JK, Gopalakrishna V, Luthra UK. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J Gen Virol 1992;73 (Part 9):2327-36.
30. Dignam JD. Preparation of extracts from higher eukaryotes. Methods Enzymol 1990;182:194-203.
31. Prusty BK, Das BC. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int J Cancer 2005;113:951-60.
32. Rosl F, Das BC, Lengert M, Geletneky K, zur Hausen H. Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription. J Virol 1997;71:362-70.
33. Fujita T, Nolan GP, Ghosh S, Baltimore D. Independent modes of transcriptional activation by the p50 and p65 subunits of NF-κB. Genes Dev 1992;6:775-87.
34. D'Costa J, Saranath D, Dedhia P, Sanghvi V, Mehta AR. Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. Oral Oncol 1998;34:413-20.
35. Sugerman PB, Shillitoe EJ. The high risk human papillomaviruses and oral cancer: evidence for and against a causal relationship. Oral Dis 1997;3:130-47.
36. Das BC, Sharma JK, Gopalkrishna V, Das DK, Singh V, Gissmann L, zur Hausen H, Luthra UK. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J Med Virol 1992;36:239-45.
37. Das BC, Gopalkrishna V, Das DK, Sharma JK, Singh V, Luthra UK. Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women. Cancer 1993;72:147-53.
38. Gopalkrishna V, Srivastava AN, Hedau S, Sharma JK, Das BC. Detection of human papillomavirus DNA sequences in cancer of the urinary bladder by in situ hybridisation and polymerase chain reaction. Genitourin Med 1995;71:231-3.
39. Jain N, Singh V, Hedau S, Kumar S, Daga MK, Dewan R, Murthy NS, Husain SA, Das BC. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India Chest 2005;128:3999-4007.
40. Balaram P, Nalinakumari KR, Abraham E, Balan A, Hareendran NK, Bernard HU, Chan SY. Human papillomaviruses in 91 oral cancers from Indian betel quid chewers - high prevalence and multiplicity of infections. Int J Cancer 1995;61:450-4.
41. Heinzel PA, Balaram P, Bernard HU. Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer 1996;68:420-3.
42. Chatterjee R, Mukhopadhyay D, Chakraborty RN, Mitra RB. Evaluation of argyrophilic nucleolar organizer regions (AgNORs) in oral carcinomas in relation to human papillomavirus infection and cytokinetics. J Oral Pathol Med 1997;26:310-14.
43. Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-κB/I κB signal transduction in the generation and treatment of human cancer. Cancer Lett 2002;181:1-9.
44. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-κB in development and progression of human cancer. Virchows Arch 2005;446:475-82.
45. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-κB signaling. Int J Cancer 2004;111:679-92.
46. Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ, Jorcano JL. Increased expression of p50-NF-κB and constitutive activation of NF-KB transcription factors during mouse skin carcinogenesis. Oncogene 1999;18:7423-31.
47. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE. NF-κB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 2001;276:45380-6.
48. Jordan RC, Catzavelos GC, Barrett AW, Speight PM. Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol 1996;32:394-400.
49. Teni T, Pawar S, Sanghvi V, Saranath D. Expression of bcl-2 and bax in chewing tobacco-induced oral cancers and oral lesions from India. Pathol Oncol Res 2002;8:109-14.
50. Harada H, Mitsuyasu T, Seta Y, Maruoka Y, Toyoshima K, Yasumoto S. Overexpression of bcl-2 protein inhibits terminal differentiation of oral keratinocytes in vitro. J Oral Pathol Med 1998;27:11-17.
51. Kurland JF, Voehringer DW, Meyn RE. The MEK/ERK pathway acts upstream of NF κB1 (p50) nomodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis. J Biol Chem 2003;278:32465-70.
52. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh NT, Mukaida N, Van Waes C. IL (interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001;7:1812-20.
53. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99:538-48.
54. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-κB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003;63:8293-301.
55. Nakayama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor κB, IκB kinase α and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 2001;92:3037-44.
56. Tamatani T, Azuma M, Aota K, Yamashita T, Bando T, Sato M. Enhanced IκB kinase activity is responsible for the augmented activity of NF-κB in human head and neck carcinoma cells. Cancer Lett 2001;171:165-72.
57. Kim S, Domon-Dell C, Wang Q, Chung DH, Di Cristofano A, Pandolfi PP, Freund JN, Evers BM. PTEN and TNF-α regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-κB-dependent pathway. Gastroenterology 2002;123:1163-78.
58. Mathas S, Johrens K, Joos S, Lietz A, Hummel F, Janz M, Jundt F, Anagnostopoulos I, Bommert K, Lichter P, Stein H, Scheidereit C, Dorken B. Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005;106:4287-93.
59. Ten RM, Paya CV, Israel N, Le Bail O, Mattei MG, Virelizier JL, Kourilsky P, Israel A. The characterization of the promoter of the gene encoding the p50 subunit of NF-κB indicates that it participates in its own regulation. Embo J 1992;11:195-203.
60. Gugasyan R, Voss A, Varigos G, Thomas T, Grumont RJ, Kaur P, Grigoriadis G, Gerondakis S. The transcription factors c-rel and RelA control epidermal development and homeostasis in embryonic and adult skin via distinct mechanisms. Mol Cell Biol 2004;24:5733-45.
61. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
62. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS, Jr. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 2000;19:1123-31.
63. Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003;23:5738-54.
64. Du J, Chen GG, Vlantis AC, Xu H, Tsang RK, van Hasselt AC. The nuclear localization of NFκB and p53 is positively correlated with HPV16 E7 level in laryngeal squamous cell carcinoma. J Histochem Cytochem 2003;51:533-9.
65. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U, Van Waes C. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468-74.
66. Roulston A, Marcellus RC, Branton PE. Viruses and apoptosis. Annu Rev Microbiol 1999;53:577-628.
67. Bowie AG, Zhan J, Marshall WL. Viral appropriation of apoptotic and NF-κB signaling pathways. J Cell Biochem 2004;91:1099-108.
68. Chong T, Chan WK, Bernard HU. Transcriptional activation of human papillomavirus 16 by nuclear factor I, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. Nucleic Acids Res 1990;18:465-70.
69. Apt D, Chong T, Liu Y, Bernard HU. Nuclear factor I and epithelial cell-specific transcription of human papillomavirus type 16. J Virol 1993;67:4455-63.
70. Vancurova I, Wu R, Miskolci V, Sun S. Increased p50/p50 NF-κB activation in human papillomavirus type 6- or type 11-induced laryngeal papilloma tissue. J Virol 2002;76:1533-6.
71. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon- responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J Virol 2001;75:4283-96.
72. Havard L, Delvenne P, Frare P, Boniver J, Giannini SL. Differential production of cytokines and activation of NF-κB in HPV-transformed keratinocytes. Virology 2002;298:271-85.
73. Woodworth CD. HPV innate immunity. Front Biosci 2002;7:d2058-d71.
74. Huang SM, McCance DJ. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol 2002;76:8710-21.
75. Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol 2005;174:7172-8.
76. Kozomara R, Jovic N, Magic Z, Brankovic-Magic M, Minic V. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. J Craniomaxillofac Surg 2005;33:342-8.
77. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto GP. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 1995;92:5451-5.
78. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol 2000;36:3-7.
79. Ito K, Sasano H, Matsunaga G, Sato S, Yajima A, Nasim S, Garret CT. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183:318-24.
80. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differenti-ated keratinocytes. Genes Dev 1995;9:2335-49.
81. Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997;11:2101-11.